Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To view this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 

Click here to view
our current issue



 
 

Shaping the Future

Traditional treatment pathways are reported to be ineffective in up to 70% of patients. In light of this, Sarah Trenfield and Dr Alvaro Goyanes at FabRx urge companies to embrace tailored therapies and, namely, 3D printing.

Sarah Trenfield and Dr Alvaro Goyanes at FabRx (April 2019)

    View full article    |    Back to Discovery Technology section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | caitlin@samedanltd.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |